Literature DB >> 317156

Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.

J V Jones, R H Cumming, P A Bacon, J Evers, I D Fraser, J Bothamley, C R Tribe, P Davis, G R Hughes.   

Abstract

Fourteen patients with active systemic lupus erythematosus (SLE) have been treated with plasmapheresis at a rate of two litres daily on three to four days per week, over a period of two to three weeks. Plasma was replaced isovolemically with either fresh frozen plasma or with human plasma protein fractions. Ten patients were receiving treatment with prednisone at the time of plasmapheresis, and four had received no prior treatment. Eight patients showed evidence of either clinical improvement or clinical and immunochemical improvement, at the time of plasmapheresis. In the three patients who showed high levels of circulating complexes before treatment, there was a sudden fall in the level of circulating immune complexes, which was quantitatively greater than could be explained by the amount removed. This suggests that in some patients with SLE, clearance of complexes by the mononuclear phagocytic system is initially blocked by high levels of circulating complexes and that one effect of plasmapheresis may be to relieve this blockade. Five patients showed a clinical response to plasmapheresis despite the fact that tests for immune complexes were negative. Three patients showed no response to plasmapheresis, and three were regarded as unevaluable. In a limited number of patients, who show a high level of circulating immune complexes, and whose condition is deteriorating despite treatment with corticosteroids, there may be an important therapeutic role for plasmapheresis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 317156

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  13 in total

Review 1.  Therapeutic approaches in mixed cryoglobulinemia.

Authors:  D Geltner
Journal:  Springer Semin Immunopathol       Date:  1988

Review 2.  Treatment of systemic lupus erythematosus.

Authors:  P A Miescher
Journal:  Springer Semin Immunopathol       Date:  1986

3.  New approaches to treating systemic lupus erythematosus.

Authors:  D Wofsy
Journal:  West J Med       Date:  1987-08

4.  Multiple mononeuropathy as the initial presentation of systemic lupus erythematosus--nerve biopsy and response to plasma exchange.

Authors:  R A Hughes; J S Cameron; S M Hall; J Heaton; J Payan; R Teoh
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

Review 5.  Immunosuppressive therapy in the treatment of autoimmune diseases.

Authors:  P A Miescher; P Beris
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study.

Authors:  W F Clark; R M Lindsay; D C Cattran; W B Chodirker; C C Barnes; A L Linton
Journal:  Can Med Assoc J       Date:  1981-07-15       Impact factor: 8.262

7.  Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis.

Authors:  A Gianviti; R S Trompeter; T M Barratt; M F Lythgoe; M J Dillon
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 8.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

9.  IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy.

Authors:  D G Scott; P A Bacon; C Allen; C J Elson; T Wallington
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

10.  Effect of plasmapheresis on T anc B lymphocyte functions in patients with systemic lupus erythematosus: a double blind study.

Authors:  G C Tsokos; J E Balow; D P Huston; N Wei; J L Decker
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.